Optimized Treatment and Regression of HBV-induced Early Cirrhosis

Inclusion criteria

• Patients from age 18 to 65 years old;
• Male or female;
• Treatment-naive patients with chronic hepatitis B histologically confirmed of early cirrhosis S4 (similar to metavir F4, Ishak 5/6) who consent to undergo liver biopsy before and after treatment;
• Patients with HBeAg-positive, HBVDNA>2×10<3>IU/ml or patients with HBeAg-negative, HBVDNA>2×10<2> IU/ml；
• Agree to be followed up regularly;
• Signature of written informed consent.

Exclusion criteria

• Patients with decompensated cirrhosis: including ascites, hepatic encephalopathy, esophageal varices bleeding or other complications of decompensated cirrhosis or hepatocelluar carcinoma;
• Patients who are allergic to entecavir, thymosin or their components, and those considered not suitable for drugs used in this study;
• Patients with HCV or HIV infection, alcoholic liver disease, autoimmune liver disease, genetic liver disease, drug-induced liver injury, severe non-alcoholic fatty liver disease or other chronic liver diseases;
• Patients with baseline AFP level higher than 100 ng/ml and possible malignant lesion on image, or AFP level higher than 100 ng/ml for more than three months;
• Creatinine >1.5×ULN;
• Patients with other uncured malignant tumors;
• Patients with severe diseases of heart, lung, kidney, brain, blood or other organs;
• Patients with any other reasons not suitable for the study.